Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers

Prostate

Volumn 74, Issue 10, 2014, Pages 1059-1067

  Chen, Zuxiong ^a   Gulzar, Zulfiqar G ^a   St Hill, Catherine A ^b   Walcheck, Bruce ^b   Brooks, James D ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

GCNT1; O glycosylation; prostate cancer; sialyl Lewis X

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; GCNT1 PROTEIN; GLYCAN; GLYCOSYLTRANSFERASE; MUCIN 1; PROSTATE SPECIFIC ANTIGEN; SIALYL LEWIS X ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHEMICAL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GLYCOSYLATION; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

GCNT1; O-GLYCOSYLATION; PROSTATE CANCER; SIALYL LEWIS X;

AGED; ANTIGENS, CD15; GLYCOSYLATION; HUMANS; MALE; MIDDLE AGED; MUCIN-1; N-ACETYLGLUCOSAMINYLTRANSFERASES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN TYROSINE PHOSPHATASES;

EID: 84901660372     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22826     Document Type: Article

References (38)

1. Apweiler R, Hermjakob H, Sharon N,. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim Biophys Acta 1999; 1473 (1): 4-8.
2. Curry JM, Thompson KJ, Rao SG, Besmer DM, Murphy AM, Grdzelishvili VZ, Ahrens WA, McKillop IH, Sindram D, Iannitti DA, Martinie JB, Mukherjee P,. The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer. J Surg Oncol 2013; 107 (7): 713-722.
3. Wu YM, Nowack DD, Omenn GS, Haab BB,. Mucin glycosylation is altered by pro-inflammatory signaling in pancreatic-cancer cells. J Proteome Res 2009; 8 (4): 1876-1886.
4. Park JH, Nishidate T, Kijima K, Ohashi T, Takegawa K, Fujikane T, Hirata K, Nakamura Y, Katagiri T,. Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis. Cancer Res 2010; 70 (7): 2759-2769.
5. Remmers N, Anderson JM, Linde EM, DiMaio DJ, Lazenby AJ, Wandall HH, Mandel U, Clausen H, Yu F, Hollingsworth MA,. Aberrant expression of mucin core proteins and O-linked glycans associated with progression of pancreatic cancer. Clin Cancer Res 2013; 19 (8): 1981-1993.
6. Prakash S, Robbins PW,. Glycotyping of prostate specific antigen. Glycobiology 2000; 10 (2): 173-176. (Pubitemid 30193017)
7. Kim EH, Misek DE,. Glycoproteomics-based identification of cancer biomarkers. Int J Proteomics 2011; 2011: 601937.
8. Peracaula R, Tabares G, Royle L, Harvey DJ, Dwek RA, Rudd PM, de Llorens R,. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology 2003; 13 (6): 457-470. (Pubitemid 36665420)
9. Tajiri M, Ohyama C, Wada Y,. Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: A glycopeptide approach. Glycobiology 2008; 18 (1): 2-8.
10. Ohyama C, Hosono M, Nitta K, Oh-eda M, Yoshikawa K, Habuchi T, Arai Y, Fukuda M,. Carbohydrate structure and differential binding of prostate specific antigen to maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. Glycobiology 2004; 14 (8): 671-679. (Pubitemid 39161974)
11. Saldova R, Fan Y, Fitzpatrick JM, Watson RW, Rudd PM,. Core fucosylation and alpha 2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology 2011; 21 (2): 195-205.
12. Brooks JD,. Translational genomics: The challenge of developing cancer biomarkers. Genome Res 2012; 22 (2): 183-187.
13. St Hill CA, Farooqui M, Mitcheltree G, Gulbahce HE, Jessurun J, Cao Q, Walcheck B,. The high affinity selectin glycan ligand C2-O-SLex and mRNA transcripts of the core 2 beta-1,6-N-acetylglucosaminyltransferase (C2GnT1) gene are highly expressed in human colorectal adenocarcinomas. BMC Cancer 2009; 9: 79.
14. St Hill CA, Bullard KM, Walcheck B,. Expression of the high-affinity selectin glycan ligand C2-O-SLeX by colon carcinoma cells. Cancer Lett 2005; 217 (1): 105-113. (Pubitemid 39642871)
15. Ni Z, Campbell JJ, Niehans G, Walcheck B,. The monoclonal antibody CHO-131 identifies a subset of cutaneous lymphocyte-associated antigen T cells enriched in P-selectin-binding cells. J Immunol 2006; 177 (7): 4742-4748. (Pubitemid 44469808)
16. Smith MJ, Smith BR, Lawrence MB, Snapp KR,. Functional analysis of the combined role of the O-linked branching enzyme core 2 beta1-6-N- glucosaminyltransferase and dimerization of P-selectin glycoprotein ligand-1 in rolling on P-selectin. J Biol Chem 2004; 279 (21): 21984-21991. (Pubitemid 38679389)
17. Walcheck B, Leppanen A, Cummings RD, Knibbs RN, Stoolman LM, Alexander SR, Mattila PE, McEver RP,. The Monoclonal antibody CHO-131 binds to a core 2 O-glycan terminated with sialyl-Lewis X, which is a functional glycan ligand for P-selectin. Blood 2002; 99 (11): 4063-4069. (Pubitemid 35332048)
18. Barthel SR, Gavino JD, Descheny L, Dimitroff CJ,. Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin Ther Targets 2007; 11 (11): 1473-1491. (Pubitemid 350200482)
19. Gulzar ZG, McKenney JK, Brooks JD,. Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1. Oncogene 2013; 32 (1): 70-77.
20. Chen Z, Prestigiacomo A, Stamey TA,. Purification and characterization of prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin: Potential reference material for international standardization of PSA immunoassays. Clin Chem 1995; 41 (9): 1273-1282.
21. Tusher VG, Tibshirani R, Chu G,. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98 (9): 5116-5121. (Pubitemid 32397092)
22. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR,. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101 (3): 811-816. (Pubitemid 38121040)
23. Stamey TA, Warrington JA, Caldwell MC, Chen Z, Fan Z, Mahadevappa M, McNeal JE, Nolley R, Zhang Z,. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J Urol 2001; 166 (6): 2171-2177. (Pubitemid 33065250)
24. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR,. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002; 1 (2): 203-209. (Pubitemid 41039166)
25. Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, Perner S, Adami HO, Fall K, Mucci LA, Kantoff PW, Stampfer M, Andersson SO, Varenhorst E, Johansson JE, Gerstein MB, Golub TR, Rubin MA, Andren O,. Molecular sampling of prostate cancer: A dilemma for predicting disease progression. BMC Med Genomics 2010; 3: 8.
26. Hagisawa S, Ohyama C, Takahashi T, Endoh M, Moriya T, Nakayama J, Arai Y, Fukuda M,. Expression of core 2 beta1,6-N-acetylglucosaminyltransferase facilitates prostate cancer progression. Glycobiology 2005; 15 (10): 1016-1024. (Pubitemid 41511496)
27. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL,. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004; 113 (6): 913-923. (Pubitemid 38544150)
28. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL,. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18 (1): 11-22.
29. Leymarie N, Griffin PJ, Jonscher K, Kolarich D, Orlando R, McComb M, Zaia J, Aguilan J, Alley WR, Altmann F, Ball LE, Basumallick L, Bazemore-Walker CR, Behnken H, Blank MA, Brown KJ, Bunz SC, Cairo CW, Cipollo JF, Daneshfar R, Desaire H, Drake RR, Go EP, Goldman R, Gruber C, Halim A, Hathout Y, Hensbergen PJ, Horn DM, Hurum D, Jabs W, Larson G, Ly M, Mann BF, Marx K, Mechref Y, Meyer B, Moginger U, Neusubeta C, Nilsson J, Novotny MV, Nyalwidhe JO, Packer NH, Pompach P, Reiz B, Resemann A, Rohrer JS, Ruthenbeck A, Sanda M, Schulz JM, Schweiger-Hufnagel U, Sihlbom C, Song E, Staples GO, Suckau D, Tang H, Thaysen-Andersen M, Viner RI, An Y, Valmu L, Wada Y, Watson M, Windwarder M, Whittal R, Wuhrer M, Zhu Y, Zou C,. Interlaboratory study on differential analysis of protein glycosylation by mass spectrometry: The ABRF Glycoprotein Research Multi-Institutional Study 2012. Mol.Cell Proteomics 2013; 12 (10): 2935-2951.
30. Okamoto T, Yoneyama MS, Hatakeyama S, Mori K, Yamamoto H, Koie T, Saitoh H, Yamaya K, Funyu T, Fukuda M, Ohyama C, Tsuboi S,. Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity. Mol Med Rep 2013; 7 (2): 359-364.
31. Madsen CB, Petersen C, Lavrsen K, Harndahl M, Buus S, Clausen H, Pedersen AE, Wandall HH,. Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response. PLoS ONE 2012; 7 (11): e50139.
32. Carson DD,. The cytoplasmic tail of MU C1: A very busy place. Sci Signal 2008; 1 (27): e35.
33. Kohlgraf KG, Gawron AJ, Higashi M, Meza JL, Burdick MD, Kitajima S, Kelly DL, Caffrey TC, Hollingsworth MA,. Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res 2003; 63 (16): 5011-5020. (Pubitemid 37022639)
34. Freire-de-Lima L, Gelfenbeyn K, Ding Y, Mandel U, Clausen H, Handa K, Hakomori SI,. Involvement of O-glycosylation defining oncofetal fibronectin in epithelial-mesenchymal transition process. Proc Natl Acad Sci USA 2011; 108 (43): 17690-17695.
35. Zhang Q, Helfand BT, Jang TL, Zhu LJ, Chen L, Yang XJ, Kozlowski J, Smith N, Kundu SD, Yang G, Raji AA, Javonovic B, Pins M, Lindholm P, Guo Y, Catalona WJ, Lee C,. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res 2009; 15 (10): 3557-3567.
36. Dimitroff CJ, Lechpammer M, Long-Woodward D, Kutok JL,. Rolling of human bone-metastatic prostate tumor cells on human bone marrow endothelium under shear flow is mediated by E-selectin. Cancer Res 2004; 64 (15): 5261-5269. (Pubitemid 39006546)
37. Rho JH, Mead JR, Wright WS, Brenner DE, Stave JW, Gildersleeve JC, Lampe PD,. Discovery of sialyl Lewis A and Lewis X modified protein cancer biomarkers using high density antibody arrays. J Proteomics 2013; 96C: 291-299.
38. Taniuchi K, Cerny RL, Tanouchi A, Kohno K, Kotani N, Honke K, Saibara T, Hollingsworth MA,. Overexpression of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell growth. Oncogene 2011; 30 (49): 4843-4854.